RP-HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-26. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
The World Health Organization has a value of 40% and this must be measured within 60 minutes of collection. WHO also has a parameter of vitality, with a lower reference limit of 60% live spermatozoa. A man can have a total number of sperm far over the limit of >16 million sperm cells per milliliter, but still have bad quality because too few of them are motile. However, if the sperm count is very high, then a low motility (for example, less than 60%) might not matter, because the fraction might still be more than 8 million per millilitre. The other way around, a man can have a sperm count far less than 20 million sperm cells per millilitre and still have good motility, if more than 60% of those observed sperm cells show good forward movement — which is beneficial because nature favours quality over quantity. A more specified measure is motility grade, where the total motility(PR+NP) and immotile. Progressively motile- Sperm moving in forward direction is Progressively Motile Non progressively Motile-Those sperms are moving circular motion are Non Progressively Motile Immotile- Those sperms are fail to move or dead sperms. The total motility reference of 40% can be divided in a 32% of progressive motility and 8% of motility in situ. Semen samples which have more than 30% progressive motility are considered as normozoospermia. Samples below that value are classified as asthenozoospermia regarding the WHO criteria.
The mass-to-charge ratio (m/Q) is a physical quantity relating the mass (quantity of matter) and the electric charge of a given particle, expressed in units of kilograms per coulomb (kg/C). It is most widely used in the electrodynamics of charged particles, e.g. in electron optics and ion optics. It appears in the scientific fields of electron microscopy, cathode ray tubes, accelerator physics, nuclear physics, Auger electron spectroscopy, cosmology and mass spectrometry. The importance of the mass-to-charge ratio, according to classical electrodynamics, is that two particles with the same mass-to-charge ratio move in the same path in a vacuum, when subjected to the same electric and magnetic fields. Some disciplines use the charge-to-mass ratio (Q/m) instead, which is the multiplicative inverse of the mass-to-charge ratio. The CODATA recommended value for an electron is Q/m = −1.75882000838(55)×1011 C⋅kg−1.
==== Section A: Cryogenics and Liquefied Gases ==== Section A on Cryogenics and Liquefied Gases focuses on refrigeration science and technology at low temperatures: the cryogenic domain spans the lower part of the temperature scale, from absolute zero to 120 K, thus encompassing the normal boiling points of air gases as well as of liquid natural gas (LNG). Section A comprises two Commissions, A1 Cryophysics and Cryoengineering, and A2 Liquefaction and Separation of Gases. Commission A1 deals with research, development and industrial activities at the lowest temperatures, including low-temperature physics, applications of superconductivity and helium cryogenics. Commission A2 essentially covers the liquefied gas industry, including air separation and LNG technology, two mature domains with high economic stakes and ongoing developments addressing important societal issues such as energy efficiency and carbon sequestration. Section A also maintains and develops relations with other Sections of the IIR, mainly Commission B1 Thermodynamics and Transfer Processes in the field of thermodynamics and transfer processes, essential tools of the cryogenic engineer, and Commission C1 Cryobiology, Cryomedicine and Health Products for the cooling of biological specimens and living tissues for preservation or treatment, which require implementing cryogenic processes.
On 5 December 2001, a 2,000lb GPS-guided bomb landed among the Green Berets from ODA 574, killing 3 members and wounding the rest of the team, over 20 of Karzai's militia were also killed and Karzai himself slightly wounded. ODB 570 and ODA 524 were immediately dispatched by helicopter to assist with the wounded and to eventually replace the fallen operators of ODA 574. ODA 572 and a CIA Jawbreaker team (small group of CIA SAD ground branch operators) were dispatched to eastern Afghanistan where they recruited some 2,500 to 3,000 into the Afghan Militia Force to take part in the Battle of Tora Bora. On December 20, following the battle, ODA 561 were inserted into the White Mountains to support ODA 572 in conducting sensitive site exploitation of the caves and to assist with recovering DNA samples from terrorist bodies. Time reported that on 4 January 2002, Green Beret SFC Scott Neil jumped out the back of an MH-53 half a mile from a suspected al-Qaeda compound, 140 miles south of Kabul. With just one-hour on-scene time due to limited helicopter fuel, Neil rushed through AK-47 fire and overcame the al-Qaeda fighters; intelligence from the compound proved it to be an al-Qaeda way station, containing hundreds of fake passports to give terrorists new identities, and multiple computers, powered by car batteries and linked to satellite phones for internet connection.
Sources: en.wikipedia.org
== Further reading == Barrett SE, Burke RS, Abrams MT, Bason C, Busuek M, Carlini E, et al. (June 2014). "Development of a liver-targeted siRNA delivery platform with a broad therapeutic window utilizing biodegradable polypeptide-based polymer conjugates". Journal of Controlled Release. 183: 124–37. doi:10.1016/j.jconrel.2014.03.028. PMID 24657948. Grazon C, Salas-Ambrosio P, Ibarboure E, Buol A, Garanger E, Grinstaff MW, et al. (January 2020). "Aqueous Ring-Opening Polymerization-Induced Self-Assembly (ROPISA) of N-Carboxyanhydrides" (PDF). Angewandte Chemie. 59 (2): 622–626. doi:10.1002/ange.201912028. PMID 31650664. S2CID 241302007. Jiang, Jinhui; Zhang, Xinyue; Fan, Zhen; Du, Jianzhong (2019-10-15). "Ring-Opening Polymerization of N-Carboxyanhydride-Induced Self-Assembly for Fabricating Biodegradable Polymer Vesicles". ACS Macro Letters. 8 (10): 1216–1221. doi:10.1021/acsmacrolett.9b00606. PMID 35651173. S2CID 203135939. Kramer JR, Onoa B, Bustamante C, Bertozzi CR (October 2015). "Chemically tunable mucin chimeras assembled on living cells". Proceedings of the National Academy of Sciences of the United States of America. 112 (41): 12574–9. Bibcode:2015PNAS..11212574K. doi:10.1073/pnas.1516127112. PMC 4611660. PMID 26420872.
== Classifications == There are six groups of anti-anxiety medications available that have been proven to be clinically significant in treatment of anxiety disorders. The groups of medications are as follows.
=== Mechanism of action === Bulevirtide binds and inactivates the sodium/bile acid cotransporter, blocking both hepatitis B and hepatitis D viruses from entering hepatocytes. The hepatitis B virus uses its surface lipopeptide pre-S1 for docking to mature liver cells via their sodium/bile acid cotransporter (NTCP) and subsequently entering the cells. Myrcludex B is a synthetic N-acylated pre-S1 that can also dock to NTCP, blocking the virus's entry mechanism. Bulevirtide is also effective against hepatitis D because the hepatitis D virus uses the same entry receptor as the hepatitis B virus and is only effective in the presence of a hepatitis B virus infection. Pre-clinical data in mice suggests that pharmacological inhibition of NTCP-mediated bile salt uptake may also be effective to lower hepatic bile salt accumulation in cholestatic conditions. This reduces hepatocellular damage. An increased ratio of phospholipid to bile salts seen in bile upon NTCP inhibition may further contribute to the protective effect as bile salts are less toxic in presence of phospholipids.
Sources: en.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
Reversed-phase HPLC is used to assess purity, and mass spectrometry confirms molecular mass. Amino acid analysis can verify composition. These methods are standard for peptide characterization.